Mark Harvey

Bio

Mark joined CM Capital in April 2006 and has over 15 years experience in medical research, technology transfer and commercialisation. He is involved in all aspects of life science investments. Mark has played key roles in the formation, fund raising and management of numerous life science companies including directorships, and has led the negotiations on numerous licensing and research collaboration deals. Prior to joining CM Capital, Mark was the Managing Director of Symbiosis Group Limited, an early stage life sciences investment company, and was Group Manager, Life Sciences for UniQuest, the commercial arm of the University of Queensland. In this role, Mark co-ordinated the commercialisation of intellectual property assets in the field of life sciences (including biotechnology) at The University of Queensland. He was a member of the Investment Committee of UniSeed, a $60million pre-seed venture fund focused on the commercialisation of technologies out of the University of Melbourne and The University of Queensland. Mark is also an Adjunct Associate Professor of The University of Queensland. Osprey Medical Inc. - (Current) Pathway Therapeutics Ltd - (Current) Sunshine Heart - (Current) BSc (Hons) Physiology, The University of Queensland, PhD, The University of Queensland, Master of Business Administration, The University of Queensland